Should You Buy Johnson & Johnson Stock Before Its Big Coronavirus Vaccine News?

Should You Buy Johnson & Johnson Stock Before Its Big Coronavirus Vaccine News?

Johnson & Johnson (NYSE: JNJ) should announce results from a late-stage study of its COVID-19 vaccine candidate, JNJ-78436735, any day now. What makes J&J's results so highly anticipated is that its vaccine requires only a single dose instead of two doses as coronavirus vaccines already on the market require. This could give J&J a significant competitive advantage over its rivals.